Macquarie rates JHC as No Rating (-1) -
Post the additional funding announced by the Australian government in response to the report by the Royal Commission into Aged Care Quality and Safety, Macquarie has updated its forecasts.
The broker sees the additional funding as positive for the aged care sector, one that supports an improved earnings outlook relative to previous expectations.
Japara Healthcare's operating income forecasts have been revised upwards by 21-36% over FY22-24.
Macquarie is research restricted and cannot provide a rating or target.
JHC Price at posting:
$1.05 Sentiment: Buy Disclosure: Held
